Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biovica International AB (publ)
  6. Ratings
    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Investment
Trading
ESG Refinitiv -
Financials
Sales Growth
Growth rating is based on the evolution of the turnover of the company between the last year and the three coming years according to consensus estimates
Earnings Growth -
EBITDA / Sales
Profitability
Profitability rating is based on net margin of the company for the current year and the next one according to consensus estimates
Finances
Finances rating is based on the evolution of the net debt of the company (debt or cash) and its Ebitda, compared to its revenue
Valuation
P/E ratio
Price Earnings Ratio rating compared the companyĺs current share price to its per-share earnings for the current fiscal year and the next one
-
EV / Sales
Valuation rating is based on the ratio between enterprise value and its turnover for the current fiscal year and the next one
Price to Book -
Price to Free Cash Flow -
Yield
"Yield" rating is based on the dividend relative to its share price
-
Momentum
Turnover review 12m
Revenue revisions (one year) rating is based on the evolution of revenue revisions of the company for the current fiscal year and the next one
Turnover review 4m
Revenue revisions (four months) rating is based on the evolution of revenue revisions of the company for the current fiscal year and the next one
Turnover review 7 days
Earnings revision 12m
EPS revisions (one year) rating is based on the evolution of EPS (earnings per share) revisions of the company for the current fiscal year and the next one
Earnings revision 4m
EPS revisions (four months) rating is based on the evolution of EPS (earnings per share) revisions of the company for the current fiscal year and the next one
Consensus
Analyst Opinion
Consensus rating is based on analyst recommendations
Potential Price Target
Potential rating is based on the average target price fixed by the consensus from Thomson Reuters
Price target revision 4m
Revision of opinion 4m -
Revision of opinion 12m -
Business Predictability
Analyst Coverage
Divergence of Estimates
Business Predictability rating is based on the dispersion of analysts' estimates on the evolution of the company business in the coming years (range estimates)
-
Divergence of analysts' opinions -
Divergence of Target Price
Earnings quality
Earnings quality rating is based on quality of past earnings released by the company compared to analysts' estimates
Technical analysis
Short Term Timing
Short Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the short term support and resistance on the basis of technical analysis in daily data
-
Middle Term Timing
Mid-Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the mid-term support and resistance on the basis of technical analysis in daily data
-
Long Term Timing
Long Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the long term support and resistance on the basis of technical analysis in daily data
-
RSI
RSI rating is based on the ranking of the security in the panel studied according to the mathematical indicator RSI 14 period
-
Bollinger Spread
Bollinger Bands rating is based on the ranking of the security in the panel studied according to the spread of the Bollinger bands
-
Unusual Volumes
Abnormal Volumes rating is based on the ranking of the security in the panel studied according to volume of the last session compared to an average session
-
Summary
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • Low profitability weakens the company.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart - Surperformance
Sector Bio Diagnostics & Testing
1st jan.Capitalisation (M$)Investor Rating
BIOVICA INTERNATIONAL AB (P..-12.70%153
EXACT SCIENCES CORPORATION-8.00%20 910
GUARDANT HEALTH, INC.-6.16%12 230
BGI GENOMICS CO., LTD.-7.00%7 659
INVITAE CORPORATION-25.33%6 239
ADAPTIVE BIOTECHNOLOGIES CO..-34.45%5 438
CAREDX, INC25.95%4 750
IOVANCE BIOTHERAPEUTICS, IN..-49.46%3 584
-
SEEGENE, INC.-35.34%2 890
VERACYTE, INC.-26.15%2 430
BEIJING STRONG BIOTECHNOLOG..-25.46%1 717
ASPIRA WOMEN'S HEALTH INC.-12.52%657
Q-LINEA AB (PUBL)-18.82%490
LYSOGENE10.57%58
ANPAC BIO-MEDICAL SCIENCE C..-16.04%58
SPAGO NANOMEDICAL AB (PUBL)0.00%36
More Results